Almirall S.A. Stock
€9.28
Your prediction
Almirall S.A. Stock
Pros and Cons of Almirall S.A. in the next few years
Pros
Cons
Performance of Almirall S.A. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Almirall S.A. | -2.060% | 1.255% | 12.827% | 11.338% | 9.563% | -34.278% | - |
Sihuan Pharmaceutical Holdings Group Ltd. | -2.210% | -2.920% | 18.750% | -23.121% | -2.920% | -78.822% | -64.628% |
Orion Corp. B | 0.690% | 0.106% | 17.424% | -7.771% | -4.189% | 3.171% | 30.588% |
Recordati SpA | -1.560% | 1.786% | 3.511% | 13.345% | 4.822% | 13.697% | - |
News
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered strong sales growth in the first
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to